Charles River to acquire Vigene Biosciences for $292.5m
The agreement also covers additional payments of up to $57.5m contingent on future performance. Charles River expects the deal to boost its gene therapy capabilities for viral vectors
Armada Acquisition has entered a definitive business combination agreement with Brains Bioceutical that values the latter at an implied pre-money equity value of about $750m.